

Haematologica
HAEMATOL/2015/124149
Version 5

Competing Risk Survival Analysis in Patients with Symptomatic
Waldenström's Macroglobulinemia: the Impact of Disease Unrelated
Mortality and of Rituximab-based primary therapy

Disclosures: there are no relevant conflicts to disclose

Contributions: EK and MAD collected and analyzed data, wrote the manuscript and performed statistical analysis, PM, MCK, MG, ET, ASS, AV, PR, SD, AS, EM, MM, EV, MV, CT, ET collected and analyzed data and critically reviewed the manuscript.